{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:11:29Z","timestamp":1793074289404,"version":"4.5.0"},"reference-count":249,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Correlates of protection (CoP) are biological parameters that predict a certain level of protection against an infectious disease. Well-established correlates of protection facilitate the development and licensing of vaccines by assessing protective efficacy without the need to expose clinical trial participants to the infectious agent against which the vaccine aims to protect. Despite the fact that viruses have many features in common, correlates of protection can vary considerably amongst the same virus family and even amongst a same virus depending on the infection phase that is under consideration. Moreover, the complex interplay between the various immune cell populations that interact during infection and the high degree of genetic variation of certain pathogens, renders the identification of immune correlates of protection difficult. Some emerging and re-emerging viruses of high consequence for public health such as SARS-CoV-2, Nipah virus (NiV) and Ebola virus (EBOV) are especially challenging with regards to the identification of CoP since these pathogens have been shown to dysregulate the immune response during infection. Whereas, virus neutralising antibodies and polyfunctional T-cell responses have been shown to correlate with certain levels of protection against SARS-CoV-2, EBOV and NiV, other effector mechanisms of immunity play important roles in shaping the immune response against these pathogens, which in turn might serve as alternative correlates of protection. This review describes the different components of the adaptive and innate immune system that are activated during SARS-CoV-2, EBOV and NiV infections and that may contribute to protection and virus clearance. Overall, we highlight the immune signatures that are associated with protection against these pathogens in humans and could be used as CoP.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1156758","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T12:57:35Z","timestamp":1681736255000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection"],"prefix":"10.3389","volume":"14","author":[{"given":"Beatriz","family":"Escudero-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Castillo-Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1086\/522432","article-title":"Correlates, surrogates, and vaccines","volume":"196","author":"Sadoff","year":"2007","journal-title":"J Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-3-540-92165-3_3","article-title":"Seasonal influenza vaccines","volume":"333","author":"Fiore","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit048","article-title":"Complex correlates of protection after vaccination","volume":"56","author":"Plotkin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/B978-0-12-387664-5.00003-0","article-title":"The control of adaptive immune responses by the innate immune system","volume":"109","author":"Schenten","year":"2011","journal-title":"Adv Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tim.2018.08.008","article-title":"Can Ebola virus vaccines have universal immune correlates of protection","volume":"27","author":"Meyer","year":"2019","journal-title":"Trends Microbiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","article-title":"An introduction to immunology and immunopathology","volume":"14","author":"Marshall","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.017","article-title":"Adaptive immunity","volume":"125","author":"Bonilla","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.07.016","article-title":"Innate immunity","volume":"125","author":"Turvey","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01736","article-title":"Principles of effective and robust innate immune response to viral infections: A multiplex network analysis","volume":"10","author":"Huang","year":"2019","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/11360","article-title":"Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon","volume":"5","author":"Cella","year":"1999","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.727046","article-title":"gammadeltaT cells are required for CD8(+) T cell response to vaccinia viral infection","volume":"12","author":"Dai","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00689-09","article-title":"Expansion, reexpansion, and recall-like expansion of Vgamma2Vdelta2 T cells in smallpox vaccination and monkeypox virus infection","volume":"83","author":"Shao","year":"2009","journal-title":"J Virol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.it.2014.06.004","article-title":"T Cell mediated immunity to influenza: Mechanisms of viral control","volume":"35","author":"La Gruta","year":"2014","journal-title":"Trends Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939550","article-title":"Generating memory with vaccination","volume":"39","author":"Castellino","year":"2009","journal-title":"Eur J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: Antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chom.2017.07.013","article-title":"Principles of broad and potent antiviral human antibodies: Insights for vaccine design","volume":"22","author":"Crowe","year":"2017","journal-title":"Cell Host Microbe"},{"key":"B20","volume-title":"Immune responses: Primary and secondary","author":"Ademokun","year":"2010"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nri891","article-title":"Antibodies, viruses and vaccines","volume":"2","author":"Burton","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1690959","DOI":"10.1080\/19420862.2019.1690959","article-title":"Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen","volume":"12","author":"Wang","year":"2020","journal-title":"MAbs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.4.2.147-153.1969","article-title":"Relative sensitivities of viruses to different species of interferon","volume":"4","author":"Stewart","year":"1969","journal-title":"J Virol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00332","article-title":"Antibody-dependent cellular phagocytosis in antiviral immune responses","volume":"10","author":"Tay","year":"2019","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0244-2","article-title":"B cell memory: Building two walls of protection against pathogens","volume":"20","author":"Akkaya","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.05.049","article-title":"Immune markers and correlates of protection for vaccine induced immune responses","volume":"30","author":"Thakur","year":"2012","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00486-7","article-title":"Bystander CD4(+) T cells: crossroads between innate and adaptive immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nri3152","article-title":"Expanding roles for CD4(+) T cells in immunity to viruses","volume":"12","author":"Swain","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040501","article-title":"Rational vaccine design in times of emerging diseases: The critical choices of immunological correlates of protection, vaccine antigen and immunomodulation","volume":"13","author":"Schijns","year":"2021","journal-title":"Pharmaceutics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ni969","article-title":"Similarities and differences in CD4+ and CD8+ effector and memory T cell generation","volume":"4","author":"Seder","year":"2003","journal-title":"Nat Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20011558","article-title":"Differential T cell function and fate in lymph node and nonlymphoid tissues","volume":"195","author":"Harris","year":"2002","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discovery"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2021.644414","article-title":"Evolution, ecology, and zoonotic transmission of betacoronaviruses: A review","volume":"8","author":"Jelinek","year":"2021","journal-title":"Front Vet Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/v14010164","article-title":"Immune profiling of COVID-19 in correlation with SARS and MERS","volume":"14","author":"Khalil","year":"2022","journal-title":"Viruses"},{"key":"B41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jaci.2020.04.027","article-title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","volume":"146","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6261","article-title":"Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/xcdary","article-title":"COVID-19, cytokines and immunosuppression: What can we learn from severe acute respiratory syndrome","volume":"38","author":"Sarzi-Puttini","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-CoV-2-Mediated inflammatory responses: From mechanisms to potential therapeutic tools","volume":"35","author":"Fu","year":"2020","journal-title":"Virol Sin"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00010.2008","article-title":"Animal models of acute lung injury","volume":"295","author":"Matute-Bello","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.chom.2020.04.017","article-title":"Heightened innate immune responses in the respiratory tract of COVID-19 patients","volume":"27","author":"Zhou","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B48","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex immune dysregulation in COVID-19 patients with severe respiratory failure","volume":"27","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B49","doi-asserted-by":"publisher","first-page":"108234","DOI":"10.1016\/j.celrep.2020.108234","article-title":"Evasion of type I interferon by SARS-CoV-2","volume":"33","author":"Xia","year":"2020","journal-title":"Cell Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1780953","article-title":"SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists","volume":"9","author":"Yuen","year":"2020","journal-title":"Emerging Microbes infections"},{"key":"B51","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41392-020-00438-7","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I\/MDA-5 signaling","volume":"5","author":"Zheng","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jaci.2020.04.029","article-title":"Type I IFN immunoprofiling in COVID-19 patients","volume":"146","author":"Trouillet-Assant","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd1554","article-title":"Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"key":"B55","volume-title":"Viral invasion and type i interferon response characterize the immunophenotypes during COVID-19 infection","author":"Wei","year":"2020"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03234-7","article-title":"Global absence and targeting of protective immune states in severe COVID-19","volume":"591","author":"Combes","year":"2021","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe7591","article-title":"Susceptibility to severe COVID-19","volume":"370","author":"Beck","year":"2020","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","first-page":"106903","DOI":"10.1016\/j.intimp.2020.106903","article-title":"Interferon \u03b2-1b in treatment of severe COVID-19: a randomized clinical trial","volume":"88","author":"Rahmani","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2020.0124","article-title":"Therapeutic effectiveness of interferon-alpha2b against COVID-19: The Cuban experience","volume":"40","author":"Pereda","year":"2020","journal-title":"J Interferon Cytokine Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-alpha2b treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12879-020-05730-z","article-title":"JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: A systematic review and meta-analysis","volume":"21","author":"Walz","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209760","article-title":"Early treatment with pegylated interferon lambda for covid-19","volume":"388","author":"Reis","year":"2023","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.02.003","article-title":"Dual nature of type I interferons in SARS-CoV-2-Induced inflammation","volume":"42","author":"King","year":"2021","journal-title":"Trends Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"107171","DOI":"10.1016\/j.intimp.2020.107171","article-title":"Potential role of interferons in treating COVID-19 patients","volume":"90","author":"Haji Abdolvahab","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.657363","article-title":"Circulating type I interferon levels and COVID-19 severity: A systematic review and meta-analysis","volume":"12","author":"da Silva","year":"2021","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1016\/j.cell.2021.08.016","article-title":"The interferon landscape along the respiratory tract impacts the severity of COVID-19","volume":"184","author":"Sposito","year":"2021","journal-title":"Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810968","article-title":"Correlation between type I interferon associated factors and COVID-19 severity","volume":"23","author":"Bencze","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000756","article-title":"Exacerbated innate host response to SARS-CoV in aged non-human primates","volume":"6","author":"Smits","year":"2010","journal-title":"PloS Pathog"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30354-4","article-title":"SARS-CoV-2 viral load predicts COVID-19 mortality","volume":"8","author":"Pujadas","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg5021","article-title":"Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients","volume":"6","author":"Notarbartolo","year":"2021","journal-title":"Sci Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.037","article-title":"Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19","volume":"183","author":"Su","year":"2020","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"B80","article-title":"Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors","author":"Braun","year":"2020","journal-title":"MedRxiv"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"B82","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0995-0","article-title":"Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19","volume":"26","author":"Juno","year":"2020","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-24377-1","article-title":"SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells","volume":"12","author":"Jung","year":"2021","journal-title":"Nat Commun"},{"key":"B86","doi-asserted-by":"publisher","first-page":"100354","DOI":"10.1016\/j.xcrm.2021.100354","article-title":"Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory b and T cells","volume":"2","author":"Cohen","year":"2021","journal-title":"Cell Rep Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"B89","article-title":"Broad and strong memory CD4 (+) and CD8 (+) T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients","author":"Peng","year":"2020","journal-title":"bioRxiv"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149535","article-title":"Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans","volume":"51","author":"Haveri","year":"2021","journal-title":"Eur J Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.770381","article-title":"Long-lasting immunity against SARS-CoV-2: Dream or reality","volume":"8","author":"Gussarow","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B94","doi-asserted-by":"publisher","first-page":"ofab378","DOI":"10.1093\/ofid\/ofab378","article-title":"SARS-CoV-2 natural antibody response persists for at least 12 months in a nationwide study from the faroe islands","volume":"8","author":"Petersen","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00143-8","article-title":"Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: A retrospective, total population cohort study in Sweden","volume":"22","author":"Nordstrom","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19102","article-title":"Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: A systematic review and pooled analysis","volume":"13","author":"Shenai","year":"2021","journal-title":"Cureus"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119497","article-title":"Effectiveness of the BNT162b2 vaccine after recovery from covid-19","volume":"386","author":"Hammerman","year":"2022","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"100902","DOI":"10.1016\/j.eclinm.2021.100902","article-title":"A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the united states","volume":"36","author":"Alfego","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.1393","article-title":"Prevalence and durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19","volume":"327","author":"Alejo","year":"2022","journal-title":"JAMA"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection","volume":"7","author":"Yang","year":"2022","journal-title":"Nat Microbiol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.02.063","article-title":"Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection","volume":"34","author":"Ng","year":"2016","journal-title":"Vaccine"},{"key":"B102","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.immuni.2020.10.004","article-title":"Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity","volume":"53","author":"Ripperger","year":"2020","journal-title":"Immunity"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab255","article-title":"Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection","volume":"224","author":"Yao","year":"2021","journal-title":"J Infect Dis"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B106","doi-asserted-by":"crossref","first-page":"100486","DOI":"10.1016\/j.xcrm.2021.100486","article-title":"A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern","volume":"3","author":"van Gils","year":"2022","journal-title":"Cell Rep Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab646","article-title":"Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants induced by natural infection or vaccination: A systematic review and pooled analysis","volume":"74","author":"Chen","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2103825","article-title":"SARS-CoV-2 antibody response in persons with past natural infection","volume":"385","author":"Anichini","year":"2021","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4292","article-title":"Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel","volume":"375","author":"Prunas","year":"2022","journal-title":"Science"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01679-5","article-title":"Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 phase 3 COVE trial","volume":"28","author":"Pajon","year":"2022","journal-title":"Nat Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263014","article-title":"Lower probability and shorter duration of infections after COVID-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs","volume":"17","author":"Ronchini","year":"2022","journal-title":"PloS One"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00801-5","article-title":"Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression","author":"Bobrovitz","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory b cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N Engl J Med"},{"key":"B115","doi-asserted-by":"crossref","first-page":"109570","DOI":"10.1016\/j.celrep.2021.109570","article-title":"Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals","volume":"36","author":"Lozano-Ojalvo","year":"2021","journal-title":"Cell Rep"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020332","article-title":"Humoral and cellular responses to COVID-19 vaccines in SARS-CoV-2 infection-naive and -recovered Korean individuals","volume":"10","author":"Hwang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266958","article-title":"Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods","volume":"17","author":"Anastassopoulou","year":"2022","journal-title":"PloS One"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4302","article-title":"Association of age with SARS-CoV-2 antibody response","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab381","article-title":"Age-dependent immune response to the Biontech\/Pfizer BNT162b2 coronavirus disease 2019 vaccination","volume":"73","author":"Muller","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266852","article-title":"Does a humoral correlate of protection exist for SARS-CoV-2? a systematic review","volume":"17","author":"Perry","year":"2022","journal-title":"PloS One"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"B122","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat Commun"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6284","article-title":"DNA Vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"B124","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-022-00979-z","article-title":"Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including omicron in rhesus macaques","volume":"7","author":"Deng","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4776","article-title":"SARS-CoV-2 infection protects against rechallenge in rhesus macaques","volume":"369","author":"Chandrashekar","year":"2020","journal-title":"Science"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41467-021-22034-1","article-title":"SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1101\/2022.09.25.22280335","article-title":"Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19","author":"Herman","year":"2022","journal-title":"medRxiv"},{"key":"B128","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cell.2022.01.014","article-title":"Multiple early factors anticipate post-acute COVID-19 sequelae","volume":"185","author":"Su","year":"2022","journal-title":"Cell"},{"key":"B129","doi-asserted-by":"publisher","first-page":"105699","DOI":"10.1016\/j.micpath.2022.105699","article-title":"Unique mutations in SARS-CoV-2 omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion","volume":"170","author":"Hossain","year":"2022","journal-title":"Microb Pathog"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01604-22","article-title":"SARS-CoV-2 variant delta potently suppresses innate immune response and evades interferon-activated antiviral responses in human colon epithelial cells","volume":"10","author":"Tandel","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10091545","article-title":"Immune evasion of SARS-CoV-2 omicron subvariants","volume":"10","author":"Ke","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B132","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","article-title":"Coronavirus envelope protein: Current knowledge","volume":"16","author":"Schoeman","year":"2019","journal-title":"Virol J"},{"key":"B133","doi-asserted-by":"publisher","first-page":"102779","DOI":"10.1016\/j.jaut.2021.102779","article-title":"Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies","volume":"126","author":"Kannan","year":"2022","journal-title":"J Autoimmun"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/v13061115","article-title":"The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation","volume":"13","author":"Bai","year":"2021","journal-title":"Viruses"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010627","article-title":"Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis","volume":"18","author":"Johnson","year":"2022","journal-title":"PloS Pathog"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41594-020-00533-x","article-title":"Author correction: SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation","volume":"27","author":"Schubert","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.antiviral.2017.11.001","article-title":"Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein","volume":"149","author":"Lei","year":"2018","journal-title":"Antiviral Res"},{"key":"B138","doi-asserted-by":"publisher","first-page":"11779322211025876","DOI":"10.1177\/11779322211025876","article-title":"Structure and function of major SARS-CoV-2 and SARS-CoV proteins","volume":"15","author":"Gorkhali","year":"2021","journal-title":"Bioinform Biol Insights"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15815","article-title":"New targets for drug design: Importance of nsp14\/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2","volume":"288","author":"Saramago","year":"2021","journal-title":"FEBS J"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-021-00916-7","article-title":"SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1","volume":"29","author":"Sun","year":"2022","journal-title":"Cell Death Differ"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.654709","article-title":"SARS-CoV-2 accessory protein ORF7b mediates tumor necrosis factor-alpha-Induced apoptosis in cells","volume":"12","author":"Yang","year":"2021","journal-title":"Front Microbiol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"167265","DOI":"10.1016\/j.jmb.2021.167265","article-title":"Mechanisms of antiviral immune evasion of SARS-CoV-2","volume":"434","author":"Beyer","year":"2022","journal-title":"J Mol Biol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016650117","article-title":"SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling","volume":"117","author":"Miorin","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B144","doi-asserted-by":"publisher","first-page":"108761","DOI":"10.1016\/j.celrep.2021.108761","article-title":"SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO","volume":"34","author":"Wu","year":"2021","journal-title":"Cell Rep"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27050","article-title":"SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I\/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways","volume":"93","author":"Han","year":"2021","journal-title":"J Med Virol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41423-020-0514-8","article-title":"SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70","volume":"17","author":"Jiang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5470.1432","article-title":"Nipah virus: a recently emergent deadly paramyxovirus","volume":"288","author":"Chua","year":"2000","journal-title":"Science"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3201\/eid2505.181076","article-title":"Nipah virus sequences from humans and bats during nipah outbreak, kerala, India, 2018","volume":"25","author":"Yadav","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"B149","article-title":"Antibody response in symptomatic & asymptomatic nipah virus cases from kerala, India","volume":"154","author":"Shete","year":"2021","journal-title":"Indian J Med Res"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01875-17","article-title":"Nipah virus infection","volume":"56","author":"Ang","year":"2018","journal-title":"J Clin Microbiol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3201\/eid1202.051247","article-title":"Nipah virus-associated encephalitis outbreak, siliguri, India","volume":"12","author":"Chadha","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"B152","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/v15030599","article-title":"Host\u2013Pathogen interactions influencing zoonotic spillover potential and transmission in humans","volume":"15","author":"Escudero-P\u00e9rez","year":"2023","journal-title":"Viruses"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/S1286-4579(01)01522-2","article-title":"Isolation of nipah virus from Malaysian island flying-foxes","volume":"4","author":"Chua","year":"2002","journal-title":"Microbes Infect"},{"key":"B154","article-title":"Nipah virus infection of pigs in peninsular Malaysia","volume":"19","author":"Mohd Nor","year":"2000","journal-title":"Rev Sci Tech"},{"key":"B155","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.virol.2010.05.005","article-title":"Characterization of the antiviral and inflammatory responses against nipah virus in endothelial cells and neurons","volume":"404","author":"Lo","year":"2010","journal-title":"Virology"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3390\/v14050936","article-title":"Henipavirus immune evasion and pathogenesis mechanisms: Lessons learnt from natural infection and animal models","volume":"14","author":"Lawrence","year":"2022","journal-title":"Viruses"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10061162","article-title":"The immunobiology of nipah virus","volume":"10","author":"Liew","year":"2022","journal-title":"Microorganisms"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00549-11","article-title":"Nipah virus uses leukocytes for efficient dissemination within a host","volume":"85","author":"Mathieu","year":"2011","journal-title":"J Virol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032157","article-title":"Lethal nipah virus infection induces rapid overexpression of CXCL10","volume":"7","author":"Mathieu","year":"2012","journal-title":"PloS One"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz010","article-title":"Adaptive immune responses in humans during nipah virus acute and convalescent phases of infection","volume":"69","author":"Arunkumar","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007454","article-title":"Peripheral immune response in the African green monkey model following nipah-Malaysia virus exposure by intermediate-size particle aerosol","volume":"13","author":"Lara","year":"2019","journal-title":"PloS Negl Trop Dis"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030855","article-title":"Nipah virus infects specific subsets of porcine peripheral blood mononuclear cells","volume":"7","author":"Stachowiak","year":"2012","journal-title":"PloS One"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1111\/j.1865-1682.2008.01021.x","article-title":"Bacterial infections in pigs experimentally infected with nipah virus","volume":"55","author":"Berhane","year":"2008","journal-title":"Transbound Emerg Dis"},{"key":"B164","doi-asserted-by":"publisher","first-page":"242ra82","DOI":"10.1126\/scitranslmed.3008929","article-title":"Therapeutic treatment of nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody","volume":"6","author":"Geisbert","year":"2014","journal-title":"Sci Transl Med"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz515","article-title":"A cross-reactive humanized monoclonal antibody targeting fusion glycoprotein function protects ferrets against lethal nipah virus and hendra virus infection","volume":"221","author":"Mire","year":"2020","journal-title":"J Infect Dis"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000642","article-title":"A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection","volume":"5","author":"Bossart","year":"2009","journal-title":"PloS Pathog"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.4.1972-1978.2006","article-title":"Antibody prophylaxis and therapy against nipah virus infection in hamsters","volume":"80","author":"Guillaume","year":"2006","journal-title":"J Virol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.2.834-840.2004","article-title":"Nipah virus: Vaccination and passive protection studies in a hamster model","volume":"78","author":"Guillaume","year":"2004","journal-title":"J Virol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"30916","DOI":"10.1038\/srep30916","article-title":"Pathogenic differences between nipah virus Bangladesh and Malaysia strains in primates: Implications for antibody therapy","volume":"6","author":"Mire","year":"2016","journal-title":"Sci Rep"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1007\/82_2012_209","article-title":"Nipah and hendra virus interactions with the innate immune system","volume":"359","author":"Basler","year":"2012","journal-title":"Curr Top Microbiol Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.11.5633-5641.2004","article-title":"Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively","volume":"78","author":"Shaw","year":"2004","journal-title":"J Virol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02610-08","article-title":"Nipah virus sequesters inactive STAT1 in the nucleus via a p gene-encoded mechanism","volume":"83","author":"Ciancanelli","year":"2009","journal-title":"J Virol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.virol.2016.07.013","article-title":"Region of nipah virus c protein responsible for shuttling between the cytoplasm and nucleus","volume":"497","author":"Horie","year":"2016","journal-title":"Virology"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.10.6078-6088.2005","article-title":"Nuclear localization of the nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways","volume":"79","author":"Shaw","year":"2005","journal-title":"J Virol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012709","article-title":"The nonstructural proteins of nipah virus play a key role in pathogenicity in experimentally infected animals","volume":"5","author":"Yoneda","year":"2010","journal-title":"PloS One"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.22.11476-11483.2002","article-title":"Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation","volume":"76","author":"Rodriguez","year":"2002","journal-title":"J Virol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06405-11","article-title":"Paramyxovirus V proteins interact with the RNA helicase LGP2 to inhibit RIG-i-dependent interferon induction","volume":"86","author":"Childs","year":"2012","journal-title":"J Virol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.virol.2006.09.023","article-title":"Mda-5, but not RIG-I, is a common target for paramyxovirus V proteins","volume":"359","author":"Childs","year":"2007","journal-title":"Virology"},{"key":"B179","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005880","article-title":"The matrix protein of nipah virus targets the E3-ubiquitin ligase TRIM6 to inhibit the IKKepsilon kinase-mediated type-I IFN antiviral response","volume":"12","author":"Bharaj","year":"2016","journal-title":"PloS Pathog"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01136-17","article-title":"Nipah and hendra virus nucleoproteins inhibit nuclear accumulation of signal transducer and activator of transcription 1 (STAT1) and STAT2 by interfering with their complex formation","volume":"91","author":"Sugai","year":"2017","journal-title":"J Virol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2007.09.005","article-title":"Ebolavirus and marburgvirus: Insight the filoviridae family","volume":"29","author":"Ascenzi","year":"2008","journal-title":"Mol Aspects Med"},{"key":"B182","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/82_2017_69","article-title":"West Africa 2013 Ebola: From virus outbreak to humanitarian crisis","volume":"411","author":"Bausch","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60667-8","article-title":"Ebola Haemorrhagic fever","volume":"377","author":"Feldmann","year":"2011","journal-title":"Lancet"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu511","article-title":"Safety and immunogenicity of DNA vaccines encoding ebolavirus and marburgvirus wild-type glycoproteins in a phase I clinical trial","volume":"211","author":"Sarwar","year":"2015","journal-title":"J Infect Dis"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: A randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study","volume":"16","author":"De Santis","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B186","doi-asserted-by":"crossref","DOI":"10.1126\/science.aab3920","article-title":"EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.09.055","article-title":"Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge","volume":"49","author":"Marzi","year":"2019","journal-title":"EBioMedicine"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000837","article-title":"Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis","volume":"4","author":"Wauquier","year":"2010","journal-title":"PloS Negl Trop Dis"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw334","article-title":"Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease","volume":"63","author":"McElroy","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2015.67","article-title":"Molecular mechanisms of Ebola virus pathogenesis: Focus on cell death","volume":"22","author":"Falasca","year":"2015","journal-title":"Cell Death Differ"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1086\/514283","article-title":"Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection","volume":"179","author":"Villinger","year":"1999","journal-title":"J Infect Dis"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004509","article-title":"Shed GP of Ebola virus triggers immune activation and increased vascular permeability","volume":"10","author":"Escudero-Perez","year":"2014","journal-title":"PloS Pathog"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001359","article-title":"Ebola Virion attachment and entry into human macrophages profoundly effects early cellular gene expression","volume":"5","author":"Wahl-Jensen","year":"2011","journal-title":"PloS Negl Trop Dis"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01800.x","article-title":"Inflammatory responses in Ebola virus-infected patients","volume":"128","author":"Baize","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B195","volume-title":"Ebola And marburg viruses: Molecular and cellular biology","author":"Klenk","year":"2004"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.14.7945-7956.2003","article-title":"The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3","volume":"77","author":"Basler","year":"2003","journal-title":"J Virol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1086\/520611","article-title":"Cytokine and chemokine expression in humans infected with Sudan Ebola virus","volume":"196","author":"Hutchinson","year":"2007","journal-title":"J Infect Dis"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.19.10370-10377.2004","article-title":"Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: Cellular responses, virus load, and nitric oxide levels","volume":"78","author":"Sanchez","year":"2004","journal-title":"J Virol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1086\/379724","article-title":"Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes\/macrophages is a key event","volume":"188","author":"Geisbert","year":"2003","journal-title":"J Infect Dis"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9100850","article-title":"Immunological perspective for Ebola virus infection and various treatment measures taken to fight the disease","volume":"9","author":"Jain","year":"2020","journal-title":"Pathogens"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.4.2208-2214.1996","article-title":"Filovirus-induced endothelial leakage triggered by infected monocytes\/macrophages","volume":"70","author":"Feldmann","year":"1996","journal-title":"J Virol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1502619112","article-title":"Human Ebola virus infection results in substantial immune activation","volume":"112","author":"McElroy","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy352","article-title":"T-Cell receptor diversity and the control of T-cell homeostasis mark Ebola virus disease survival in humans","volume":"218","author":"Speranza","year":"2018","journal-title":"J Infect Dis"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T Cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1806200115","article-title":"Analysis of CD8(+) T cell response during the 2013-2016 Ebola epidemic in West Africa","volume":"115","author":"Sakabe","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/nature17949","article-title":"Unique human immune signature of Ebola virus disease in Guinea","volume":"533","author":"Ruibal","year":"2016","journal-title":"Nature"},{"key":"B207","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nm0198-037","article-title":"Immunization for Ebola virus infection","volume":"4","author":"Xu","year":"1998","journal-title":"Nat Med"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780021","article-title":"Apoptosis induced in vitro and in vivo during infection by Ebola and marburg viruses","volume":"80","author":"Geisbert","year":"2000","journal-title":"Lab Invest"},{"key":"B209","doi-asserted-by":"publisher","first-page":"43776","DOI":"10.1038\/srep43776","article-title":"Ebola Virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination","volume":"7","author":"Ludtke","year":"2017","journal-title":"Sci Rep"},{"key":"B210","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-642-59949-1_7","article-title":"Pathologic features of filovirus infections in humans","volume":"235","author":"Zaki","year":"1999","journal-title":"Curr Top Microbiol Immunol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2478(01)00327-3","article-title":"Proinflammatory response during Ebola virus infection of primate models: Possible involvement of the tumor necrosis factor receptor superfamily","volume":"80","author":"Hensley","year":"2002","journal-title":"Immunol Lett"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2478(99)00058-9","article-title":"Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125-kDa GP viral protein","volume":"68","author":"Chepurnov","year":"1999","journal-title":"Immunol Lett"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00845-17","article-title":"Ebola Virus binding to Tim-1 on T lymphocytes induces a cytokine storm","volume":"8","author":"Younan","year":"2017","journal-title":"mBio"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008068","article-title":"Ebola Virus-mediated T-lymphocyte depletion is the result of an abortive infection","volume":"15","author":"Younan","year":"2019","journal-title":"PloS Pathog"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1038\/7422","article-title":"Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients","volume":"5","author":"Baize","year":"1999","journal-title":"Nat Med"},{"key":"B216","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1009657006550","article-title":"Apoptosis in fatal Ebola infection. does the virus toll the bell for immune system","volume":"5","author":"Baize","year":"2000","journal-title":"Apoptosis"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.3201\/eid1507.090402","article-title":"Immunoglobulin G in Ebola outbreak survivors, Gabon","volume":"15","author":"Wauquier","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1086\/514321","article-title":"Clinical virology of Ebola hemorrhagic fever (EHF): Virus, virus antigen, and IgG and IgM antibody findings among EHF patients in kikwit, democratic republic of the Congo, 1995","volume":"179","author":"Ksiazek","year":"1999","journal-title":"J Infect Dis"},{"key":"B219","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/9bc62f9e-8386-4e9b-951c-1eeba930a41c","article-title":"High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon","volume":"5","author":"Becquart","year":"2010","journal-title":"PloS One"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix584","article-title":"Ebola Virus neutralizing antibodies detectable in survivors of theYambuku, Zaire outbreak 40 years after infection","volume":"217","author":"Rimoin","year":"2018","journal-title":"J Infect Dis"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.009","article-title":"Towards quantification of protective antibody responses by passive transfer of the 1st WHO international standard for Ebola virus antibody in a guinea pig model","volume":"38","author":"Dowall","year":"2020","journal-title":"Vaccine"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Science"},{"key":"B223","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","article-title":"Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection","volume":"164","author":"Flyak","year":"2016","journal-title":"Cell"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"B225","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates","volume":"25","author":"Bornholdt","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030009","article-title":"Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys","volume":"3","author":"Oswald","year":"2007","journal-title":"PloS Pathog"},{"key":"B227","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1038\/s41598-017-06226-8","article-title":"Sudan Ebolavirus long recovered survivors produce GP-specific abs that are of the IgG1 subclass and preferentially bind FcgammaRI","volume":"7","author":"Radinsky","year":"2017","journal-title":"Sci Rep"},{"key":"B228","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.cell.2019.04.036","article-title":"Longitudinal analysis of the human b cell response to Ebola virus infection","volume":"177","author":"Davis","year":"2019","journal-title":"Cell"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz364","article-title":"Survivors of Ebola virus disease develop polyfunctional antibody responses","volume":"221","author":"Gunn","year":"2020","journal-title":"J Infect Dis"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599568","article-title":"Ebolavirus: Comparison of survivor immunology and animal models in the search for a correlate of protection","volume":"11","author":"Longet","year":"2020","journal-title":"Front Immunol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1414164111","article-title":"Structures of protective antibodies reveal sites of vulnerability on Ebola virus","volume":"111","author":"Murin","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B234","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.immuni.2020.01.001","article-title":"Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization","volume":"52","author":"Gilchuk","year":"2020","journal-title":"Immunity"},{"key":"B235","doi-asserted-by":"publisher","first-page":"108984","DOI":"10.1016\/j.celrep.2021.108984","article-title":"Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies","volume":"35","author":"Murin","year":"2021","journal-title":"Cell Rep"},{"key":"B236","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.coi.2021.03.008","article-title":"Ebola Virus disease: current vaccine solutions","volume":"71","author":"Tomori","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010078","article-title":"Current state of Ebola virus vaccines: A snapshot","volume":"17","author":"Woolsey","year":"2021","journal-title":"PloS Pathog"},{"key":"B238","doi-asserted-by":"publisher","first-page":"100920","DOI":"10.1016\/j.isci.2020.100920","article-title":"Human antibody repertoire following Ebola virus infection and vaccination","volume":"23","author":"Fuentes","year":"2020","journal-title":"iScience"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202000069","article-title":"Epitopes of naturally acquired and vaccine-induced anti-Ebola virus glycoprotein antibodies in single amino acid resolution","volume":"15","author":"Heidepriem","year":"2020","journal-title":"Biotechnol J"},{"key":"B240","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3390\/v12090915","article-title":"Ebola Virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins","volume":"12","author":"Koch","year":"2020","journal-title":"Viruses"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2014.0066","article-title":"Immune evasion in ebolavirus infections","volume":"28","author":"Audet","year":"2015","journal-title":"Viral Immunol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002550","article-title":"The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold","volume":"8","author":"Zhang","year":"2012","journal-title":"PloS Pathog"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02349-05","article-title":"Ebola Virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation","volume":"80","author":"Reid","year":"2006","journal-title":"J Virol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01006-06","article-title":"The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR","volume":"81","author":"Feng","year":"2007","journal-title":"J Virol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003258","article-title":"The secret life of viral entry glycoproteins: moonlighting in immune evasion","volume":"9","author":"Cook","year":"2013","journal-title":"PloS Pathog"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.8.3602","article-title":"The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing","volume":"93","author":"Sanchez","year":"1996","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003065","article-title":"Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus","volume":"8","author":"Mohan","year":"2012","journal-title":"PloS Pathog"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.16.10442-10450.2005","article-title":"Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function","volume":"79","author":"Wahl-Jensen","year":"2005","journal-title":"J Virol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.3390\/v11110999","article-title":"The roles of Ebola virus soluble glycoprotein in replication, pathogenesis, and countermeasure development","volume":"11","author":"Zhu","year":"2019","journal-title":"Viruses"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1156758\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T22:32:10Z","timestamp":1682029930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1156758\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":249,"alternative-id":["10.3389\/fimmu.2023.1156758"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1156758","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"article-number":"1156758"}}